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ABSTRACT 
Post-operative vitreous cavity hemorrhage (POVCH) is observed in 6-75% of eyes undergoing pars plana vitrectomy 
(PPV) for proliferative diabetic retinopathy (PDR). We describe our technique for office-based Air fluid exchange (AFX) 
in the treatment of POVCH. Sixteen eyes (15 patients) with PDR and POVCH undergoing office-based AFX between 
January 2006 and November 2016 were retrospectively identified. The pre- and post- procedure visual acuity (VA) and 
complications were compared between eyes with and without traction retinal detachment (TRD). Medicare charges for 
office-based AFX versus PPV were also analyzed. Mean (± standard deviation [SD]) age at the time of AFX was 55.31 (± 
8.02) years. Nine eyes (56.25%) had TRD prior to PPV and 11 eyes (68.75%) were pseudophakic. The improvements in 
mean (±SD) logMAR VA at the last postoperative visit (3 - 8 months) were 1.38 (± 0.99), 0.82 (± 0.91) and 2.09 (± 0.53) in 
all eyes, TRD eyes and non-TRD eyes, respectively. Complications included cataract progression, hypotony, and 
recurrence of TRD and ghost cell glaucoma. The total cost of outpatient AFX was $1,409.59 less than that of PPV. Office-
based AFX is a cost-effective alternative treatment for non-clearing diabetic POVCH with an acceptable risk profile. 
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INTRODUCTION
Postoperative vitreous cavity hemorrhage (POVCH) is a 
relatively common complication, observed in up to 75% 
of eyes following pars plana vitrectomy (PPV) in the 
setting of proliferative diabetic retinopathy (PDR) [1-6]. 
While most cases of POVCH result in spontaneous 
clearing, repeat PPV is required in 10-38% of cases where 
POVCH persists [1, 2, 4]. 
Air fluid exchange (AFX) is an alternative treatment 
approach to PPV for POVCH that can be undertaken in an 
office-based setting [7-10]. There is a paucity of 
contemporary literature on the efficacy and safety of 
office-based AFX for POVCH, with earlier studies 
describing cataract formation, iris neovascularization and 
anterior hyaloid fibrovascular proliferation as main 
complications [8-10]. As patient characteristics have 
changed with modern vitrectomy instrumentation, 
earlier cataract surgery, more effective laser treatment 
and integration of intravitreal anti-vascular endothelial 
growth factor (VEGF) injections into the treatment of 
diabetic macular edema and PDR, there is a need for 
contemporary re-evaluation of this treatment approach. 
With a renewed emphasis on the cost of healthcare, a 
modern-day comparison of the cost effectiveness of 
office-based AFX versus PPV is valuable.  
We conducted a retrospective chart review study of eyes 
that underwent office-based AFX for POVCH at our 
institution. We described their visual outcomes and post-
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procedure complications and presented a cost-
comparison of office-based AFX versus PPV. 
METHODS 
Data Categorization 
We retrospectively reviewed electronic charts of adult 
patients (age >18 years) who underwent office-based 
AFX for the treatment of POVCH between January 2006 
and November 2016 at the University of Arkansas for 
Medical Sciences, State of Arkansas, United States. 
Patients were identified through current procedure 
terminology (CPT) code search in the electronic medical 
record (Epic, Epic System Corporation, Verona, WI). We 
collected data including age, sex, laterality, visual acuity 
(VA), duration of post-AFX follow-up, time interval from 
initial PPV to POVCH, duration of POVCH, post-procedure 
complications, history of tractional retinal detachment 
(TRD) and crystalline lens status. Visual acuity, recorded 
as counting fingers (CF), hand motions (HM), light 
perception (LP) and no light perception (NLP) were 
converted to 2.1, 2.4, 2.7, and 3.00 logMAR, respectively 
[11]. We included both eyes when both had undergone 
the procedure and excluded eyes with less than 3 
months of follow-up and those with vitreous cavity 
hemorrhage secondary to causes other than PDR. Visual 
improvement after AFX was defined as a gain of 0.3 
LogMAR or more (approximately 2 Snellen lines) [12]. 
This study was conducted in compliance with the 
Declaration of Helsinki and ethical approval was obtained 
from ethical committee for research of University of 
Arkansas for Medical Sciences.  
Office-based Air-Fluid Exchange Technique 
Our technique for office-based AFX differs slightly from 
those previously described [7-10]. First, B-scan 
ultrasonography is performed to exclude a retinal 
detachment. Then, the patient is placed in a reclined 
position. After topical anesthesia, the eye is prepped 
with a 5% povidone iodine solution and a lid speculum is 
placed. Using sterile technique and an air filter, a 10 mL 
syringe is filled with sterile air. A half-inch 30-gauge 
needle is then attached and inserted superotemporally 
(nondependent position) through the pars plana into the 
vitreous cavity. A second 30-gauge needle, attached to a 
10 mL syringe, is then inserted through the pars plana at 
6 O’clock (dependent position) into the vitreous cavity. 
Injection of air through the nondependent syringe is 
performed, matching the rate of aspiration of the 
hemorrhage through the dependent syringe. The 
procedure is continued until air is observed in the 
dependent syringe and is typically performed in less than 
10 minutes. 
Main Outcome Measures 
Visual acuity and post-procedure complications were 
considered as primary outcomes for this study. For 
analyses, visual outcome data was further segregated by 
history of TRD and the time to onset and observation 
duration of POVCH. Costs were analyzed using Medicare 
fee data and CPT codes which were used to calculate 
facility and non-facility fees, using a standard 2016 
relative value unit (RVU) cost of $35.8887 per RVU [12, 
13]. 
Anesthesia fees were calculated on base and time units 
with a conversion factor of $22.0454 [14]. 
Continuous variables were summarized as mean and 
range values and additional statistical analyses were 
performed using statistics calculators of the online forum 
Social Science Statistics. The Wilcoxon signed-rank test 
was used for the assessment of VA, the Mann-Whitney U 
test for continuous data, the Fisher exact test for 
categorical data and the Spearman’s Rho test for 
correlations. A p-value less than 0.05 was considered as 
statistically significant difference.  
RESULTS 
Sixteen eyes of 15 patients were included in this study. 
Demographic and visual outcome data are shown in 
Table 1. Of the 16 eyes in the study, 9 eyes (56.25%) had 
persistent (onset < 3 months after PPV) and 7 eyes 
(43.75%) had recurrent (onset > 3 months after PPV) 
POVCH. Eleven eyes (68.75%) were pseudophakic and 5 
(31.25%) were phakic. Four eyes (25%) had received 
intravitreal anti-VEGF or steroid injections prior to AFX 
and 5 (31.25%) received such treatments post-AFX. All 
eyes underwent at least one session of panretinal 
photocoagulation (PRP) before or soon after AFX. The 
mean (± standard deviation [SD]) duration of post-AFX 
follow-up was 6.19 (± 1.34) months (median: 6.5 months, 
range: 3.5 - 8 months) and three eyes (18.75%) required 
a second AFX procedure.  
Prior to AFX, the mean VA (± SD) was 2.38 (± 0.17) 
logMAR (~ HM) (range: 2.1 to 2.7 logMAR). After AFX, the 
mean VA (±SD) was 1.31 (± 0.97) LogMAR (~ 20/400 
Snellen VA) at 3-month post procedure visit and 1.04 (± 
0.96) LogMAR (~ 20/200 Snellen VA) at the last post-
procedure visit which was recorded between 3 and 8 
months after AFX. Of 16 eyes in this study, 14 showed 
improvement in VA after AFX. The mean improvement in 
VA at 3 months was 0.93 logMAR units (~ 6 Snellen lines), 
which was statistically significant (P = 0.004, Wilcoxon 
signed-rank test). The mean improvement in VA at the 
final follow-up was 1.38 logMAR units (~ 9 Snellen lines) 
and this was also statistically significant (p = 0.001, 
Wilcoxon signed-rank test). 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(2)  
 
106 AIR-FLUID EXCHANGE IN DIABETIC POST-OPERATIVE VITREOUS HEMORRHAGE 
Prior to PPV surgery, 8 eyes (50%) had TRD with macular 
involvement and one eye had TRD without macular 
involvement. The mean (±SD) improvement in VA was 
0.82 (± 0.91) logMAR units with TRD and 2.09 (± 0.53) 
logMAR units without TRD (p = 0.015, Mann-Whitney 
test). Four of the 9 eyes (44.4%) with TRD and all 7 eyes 
without TRD achieved a VA of 1.3 logMAR (~ 20/400 
Snellen VA) or better (P = 0.034, Fisher’s exact test). The 
time to onset (following PPV) and observation duration 
of POVCH were negatively associated with post-AFX 
improvement in VA significantly (P = 0.02 and P = 0.02, 
respectively, Spearman Rho’s test). No intra-procedural 
complications were encountered. Post-procedure 
complications are described in Table 2 including 
worsening of cataract in all 5 phakic eyes, ocular 
hypertension (intraocular pressure [IOP] > 22mmHg) in 
3/16 eyes (18.75%), hypotony (IOP < 6mmHg) in 1/16 
eyes (6.25%), recurrence of TRD in 2/9 eyes (22.22%), iris 
neovascularization in 1/16 eyes (6.25%) and ghost cell 
glaucoma in 1/16 eyes (6.25%). Four of the five phakic 
eyes (80%) required cataract surgery with a mean time to 
cataract surgery of 3 months (median: 3 months, range: 
1.5 - 6 months) following AFX. Three eyes (18.75%) 
required repeat PPV after AFX for recurrence of TRD and 
new retinal breaks. Two of these three eyes showed no 
improvement in VA after repeat PPV. The costs 
associated with office-based AFX and repeat PPV are 
described in Table 3. The charges for office-based AFX, 
performed in a hospital-associated outpatient setting, 
include non-facility fee of $737.15 [13, 14]. 
For AFX performed in a non-hospital associated 
outpatient clinic, no facility fee is applied and the overall 
charge for AFX consists only of a professional fee of 
$737.15. The fees associated with a 30-minute PPV in the 
operating room in an ambulatory surgery center (ASC) 
not owned by operating surgeons include anesthesia fee 
of $176.36 [15], and hospital/ambulatory surgery center 
facility fee of $1750.01  [14] and surgeon professional fee 
of $916.60, resulting in a total of $1092.96. 
 
 
Table 1: Patient Characteristics Before and After Air Fluid Exchange Procedure 
Case 
Age, Race 
and 
Gender 
Persistent 
vs. 
Recurrent 
POVCH 
Post-
PPV 
Time 
Interval 
(month) 
POVCH 
Duration 
(week) 
Pre-AFX 
logMAR 
VA 
No. AFX 
Procedures 
Repeat PPV/ 
indication 
Lens Status TRD PRP 
Intravitreal 
Anti-VEGF / 
Steroid 
(pre/post- 
AFX) 
Post-
AFX 
logMAR 
VA 
(most 
recent) 
Complications 
Follow- 
Up 
Duration 
(month) 
1 67, AAF Recurrent 23 1.28 2.4 1 No Pseudophakic No Yes 
Bevacizumab 
x 2 (post) 
0.5 None 6 
2 65, CF Persistent 2 4.28 2.7 1 No Phakic No Yes 
Bevacizumab 
x 1 (post) 
0 Cataract 7.5 
3 59, CM Persistent 1.16 5 2.4 1 
Yes (new 
retinal breaks, 
ERM) 
Phakic Yes Yes 
Bevacizumab 
x 1 (pre) 
Bevacizumab 
x 1 (post) 
2.1 NVI, Cataract 6.5 
4 64, AAF Recurrent 6 9 2.7 1 No Pseudophakic Yes Yes None 3.0 None 7.5 
5 41, AAF Recurrent 6 4.28 2.4 2 No Pseudophakic No Yes None 0.4 None 7 
6 53, AAM Persistent 2 4.28 2.1 1 
Yes (recurrent 
VH, ERM) 
Pseudophakic Yes Yes None 2.1 
Recurrent 
TRD 
6.5 
7 47, AAM Persistent 9 39.4 2.4 1 
Yes (new TRD, 
ERM) 
Phakic Yes Yes None 2.1 
Recurrent 
TRD, 
hyphema, 
cataract 
7.5 
8 48, AAF Recurrent 10 2 2.4 1 No Phakic Yes Yes None 1.3 
Recurrent 
TRD, 
cataract 
6 
9 53, CF Persistent 0.23 1 2.4 1 No Pseudophakic Yes Yes None 0.2 None 6.5 
10* 52, AAM Persistent 0.23 1 2.7 2 No Pseudophakic No Yes 
Bevacizumab 
x 1 (pre) 
0.6 None 4.5 
11* 52, AAM Persistent 0.13 2 2.4 1 No Pseudophakic Yes Yes 
Bevacizumab 
x 1 (pre) 
0.4 
Ghost cell 
glaucoma 
7 
12 54, HF Recurrent 15 4.28 2.4 2 No Pseudophakic Yes Yes None 1.3 None 3.5 
13 46, CF Recurrent 17 3 2.4 1 No Pseudophakic Yes Yes None 2.1 None 3.5 
14 57, AAF Persistent 0.93 3 2.1 1 No Pseudophakic Yes Yes 
Aflibercept x 
3 (pre), 
Aflibercept x 
1 (post) 
0.6 None 5 
15 58, AAM Persistent 0.07 1.71 2.7 1 No Phakic No Yes 
Bevacizumab 
x 1 (post) 
0.1 
Hyphema, 
cataract 
6.5 
16 69, CM Persistent 0.07 3 2.4 1 No Pseudophakic No Yes None 0.2 none 8 
Abbreviations: AAF: African American female; AAM: African American male; AFX: air-fluid exchange; Anti-VEGF: Anti–vascular endothelial growth factor; 
CF: Caucasian female; CM: Caucasian male; ERM: epiretinal membrane; HF: Hispanic female; NVI: neovascularization of iris; POVCH: post-operative 
vitreous cavity hemorrhage; PPV: pars plana vitrectomy; PRP: panretinal photocoagulation; TRD: tractional retinal detachment; VA: visual acuity; logMAR: 
Logarithm of the minimum angle of resolution; V.S: Versus; VH: vitreous hemorrhage. *Study eyes number 10 and 11 are from the same patient. 
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Table 2: Post air-fluid exchange (AFX) Complications. 
Complications No. of eyes 
      Hypotony 1 (6.7%) 
Elevated IOP (1wk post AFX)   
IOP (30-40) mmHg 1 (6.7%) 
IOP (22-30) mmHg 2 (13.3%)* 
Hyphema  2 (13.3%) 
Worsening cataract requiring surgery 5/5 (100%) 
Cataract surgery post AFX 5 (100%) 
Recurrent TRD 3/9 (33.3%) 
NVI 1/16 (6.7%) 
Ghost cell glaucoma 1/16 (6.7%) 
Post air-fluid exchange complications include hypotony, elevated intraocular pressure (IOP), hyphema, cataract progression, recurrent traction retinal 
detachment (TRD) and neovascularization of iris (NVI). Numbers of eyes with each complication are listed. * Intraocular pressure (IOP) in all three cases 
after air-fluid exchange was lower than pre-air-fluid exchange IOP. Abbreviation: AFX: air-fluid exchange; wk: week; mmHg: millimetre of mercury. 
 
Table 3: Cost Analysis of Air-Fluid Exchange performed in Clinic Versus Pars Plana Vitrectomy Performed in an Operating Room at an Ambulatory 
Surgery Center. 
 AFX (CPT code 67025) PPV (CPT code 67036 without modifier) 
Total RVU  20.54 25.54 
Professional fee   
price $737.15 $916.60 
limiting charge $805.34 $1001.38 
ASC payment N/A $1750.01 
Anesthesia fee (30-minute) N/A $176.36 
Total fees  $737.15 $2843.97 
Total fees limits   $ 805.34 $ 2927.75 
Total revenue value unit (RVU) is the sum of work RVU, facility or non-facility RVU and malpractice RVU, based on 2017 Medicare physician fee schedule. 
Professional fee is the amount of reimbursement for the physician based on total RVU multiplied by national conversion factor 35.8887, and the limiting 
charge is the upper limit payment for physicians, which is usually 115% of the professional fee, as provided by the 2017 Medicare physician fee schedule 
using the fee of national payment schedule as the Medicare administrative contractor option. Ambulatory surgery center (ASC) payment Anesthesia fee is 
calculated based on base unit of CPT code 00145 for 30 minutes of vitreoretinal surgery. Total fees are the sum of hospital or ambulatory surgery center 
professional fee, ASC facility fee and anesthesia fee. Total fees limits are the sum of ASC payment and anesthesia fee. Abbreviations: AFX: air-fluid 
exchange; PPV:  Pars Plana Vitrectomy; CPT: current procedural terminology. 
DISCUSSION 
We described visual outcomes, post-procedure 
complications and relative cost of office-based AFX for 
POVCH in the setting of PDR. We found a notable 
improvement in mean VA of 1.38 logMAR units (~ 9 
Snellen lines), with 14 of 16 eyes showing improvement. 
Eyes with TRD showed less improvement than those 
without it, with a gain of 0.82 versus 2.09 logMAR units, 
respectively. We found negative associations between 
vision improvement and the time to onset and the 
observation duration of POVCH. We calculated a 
difference in expenses up to $2121.45 when comparing 
office-based AFX to a 30-minute PPV (CPT 67036) in the 
operating room. 
The visual improvement we found with office-based AFX 
was not substantially different from those previously 
described. A study by Martin and McCuen reported a 
median pre-AFX VA of 2.45 logMAR (HM) and a median 
post-AFX visual acuity of 0.30 logMAR (20/40 Snellen VA) 
for AFX alone [10]. Another study by Han, et al. found 
median pre- and post-AFX visual acuities of 2.4 logMAR 
(HM) and 1.20 logMAR (20/300 Snellen VA), respectively 
[9]. Our median pre- and post-AFX visual acuities were 
2.4 logMAR (HM) and 0.95 logMAR (20/200 Snellen VA), 
respectively. In a study by Blankenship examining post-
AFX visual outcomes, 12/19 eyes (63%) improved to 0.95 
logMAR (20/200 Snellen VA) or better with AFX [8]. In 
our study, 8/16 eyes (50%) improved to this level of 
vision. We found better outcomes in eyes without TRD 
and those with a shorter time to onset and observation 
duration of POVCH, likely secondary to better pre-AFX 
vision potential in these eyes. 
Regarding the efficacy of AFX as a treatment for POVCH, 
it is also important to assess the number of eyes 
requiring repeat AFX procedures and / or PPV for a non-
clearing hemorrhage. In the study by Martin and 
McCuen, the mean number of AFX procedures 
performed per patient was 1.5, with 40% requiring a 
repeat vitrectomy [10]. In the study by Han et al., the 
mean number of AFX procedures per eye was 1.75, with 
25% eyes requiring a repeat vitrectomy [9]. And in our 
study, the mean number of AFX procedures per eye was 
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1.2, with 3 of 16 eyes (19%) requiring a repeat 
vitrectomy.  
We observed a lower incidence of post procedure 
complications with AFX than previously described [7-10]. 
Prior studies have noted cataract to be a major 
complication of AFX, with cataract development reported 
in up to 59% of eyes [8-10]. However, 84-92% of the eyes 
in these studies were phakic at the time of AFX versus 
only 31% in our study. Other complications noted 
previously include iris neovascularization (12-26.3%), 
anterior hyaloidal fibrovascular proliferation (5-12.5%), 
neovascular glaucoma (12-37%) and ghost cell glaucoma 
(5%) [8-10]. Notably the risk of fibrovascular 
complications in our study was substantially lower; iris 
neovascularization in 1 eye (6.25%), ghost cell glaucoma 
in 1 eye (6.25%) and no cases of anterior hyaloid 
fibrovascular proliferation. Over the past 20 years, 
cataract surgery has become more prevalent in the 
United States [16, 17].
 
In addition to negating a concern 
for cataract development in these patients after PPV or 
AFX, pseudophakia offers a benefit over aphakia for 
decreased VEGF circulation from the posterior segment 
and thus possibly a reduced risk of neovascular 
complications [18]. Modern vitrectomy may have 
contributed to decreased risk of iris neovascularization, 
neovascular glaucoma and anterior hyaloid fibrovascular 
proliferation found in our study. Compared to the early 
era of vitrectomy, small gauge, high speed vitrectomy 
instruments and improved endolaser systems enable 
more thorough relief of vitreoretinal traction and 
treatment of retinal ischemia [19-21]. Further, the 
reduced risk of fibrovascular complications may also be 
related to the current trend of improved preoperative 
control of PDR with laser and intravitreal anti-VEGF 
treatments. 
With recent concern for the rising cost of healthcare with 
an aging population, physicians are more mindful of care-
associated costs. Office-based AFX is a clinic-based 
procedure, which takes less time and planning than does 
a transfer to the operating room. In a carefully selected 
patient population recurrent vitreous cavity hemorrhage 
after PPV in the absence of TRD and pseudophakic eyes, 
office-based AFX is an effective and cost effective first 
line procedure to clear the hemorrhage. The success rate 
of clearing vitreous cavity hemorrhage at 3-8 months 
post-procedure is 81% (13 of 16 eyes) with single AFX 
(Table 1). Having the AFX performed in the 
ophthalmologist clinic, ASC or hospital facility fee as well 
as anesthesia fee are non-existing. Based on the 2017 
Medicare physician fee schedule, ASC payment rate and 
anesthesia fee schedule [13, 14], the procedure payment 
for office-based AFX (CPT 67025) was 2104.93 less than a 
30-minute PPV performed in ASC (CPT 67036) (Table 3). 
This study is limited by its small size, retrospective design 
and short follow-up time. It could also be subject to 
selection bias, as cases of worse POVCH or those with 
more significant preoperative TRD may have been 
treated with repeat PPV. This may explain the small 
number of cases in our study. Also, the differences in the 
reporting of visual outcomes make comparison to 
previous studies difficult. Follow-up time past 3 months 
was inconsistent and we reported final VA measured at 3 
to 8 months as our primary visual outcome. Office-based 
AFX does not allow physicians to address worsening 
traction as a cause for bleeding and will not allow for the 
removal of large clots. Finally, outcomes may have also 
been affected by pre-procedure vision potential. Despite 
these limitations, our study is a useful examination of 
office-based AFX in the setting of POVCH and the use of 
contemporary vitrectomy instruments and anti-VEGF 
treatments for diabetic retinopathy. It also offers a 
modern-day cost comparison to repeat PPV. 
CONCLUSIONS 
In conclusion, office-based AFX is a useful and cost-
conscious alternative treatment for patients with POVCH 
secondary to PDR, particularly in the absence of TRD and 
pseudophakic patients. Office based AFX is also useful for 
patients who have multiple recurrent POVCH despite 
multiple PPV and endolasers, as well as for those who are 
high risk patients to undergo general anesthesia or 
retrobulbar block. We found that improvement in mean 
VA of 1.38 logMAR units (~ 9 Snellen lines) was 
comparable to previous studies, with greater 
improvements noted in patients without TRD and those 
with earlier onset and shorter duration of observation. 
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